N/A
Completed N=58
Correction of Farsightedness in Children Study
Hyperopia · Farsightedness
Source: ClinicalTrials.gov NCT00472212 ↗
Enrolled (actual)
58
Serious AEs
0.0%
Results posted
Aug 2022
Primary outcomePrimary: Change in Kaufman Test of Educational Achievement (K-TEA) Reading Comprehension Score as Measured From Baseline to After 6 Weeks of Assigned Treatment (Hyperopic or Control Correction) — -2.92; 0.088 score on a scale
Summary
The Correction of Hyperopia In Children Study (CHICS) is a placebo-controlled, randomized, masked investigation of the effect of spectacle correction for moderate amounts of hyperopia on visual function, attention, and reading skills in children.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Kaufman Test of Educational Achievement (K-TEA) Reading Comprehension Score as Measured From Baseline to After 6 Weeks of Assigned Treatment (Hyperopic or Control Correction) |
-2.92; 0.088 | — |
| SECONDARY Change in Cognitive Assessment System (CAS) Attention Scores as Measured From Baseline to After 6 Weeks of Assigned Treatment (Hyperopic or Control Correction) |
9.14; 3.46 | — |
| SECONDARY Change in Accommodative Response From Baseline to After 6 Weeks of Assigned Treatment (Hyperopic or Control Correction) |
0.23; 0.054 | — |
Eligibility Criteria
Inclusion Criteria
- Age 6-11 years;
- At least +1.00D Hyperopia (farsightedness);
- < +4.00D Hyperopia;
- < 1.00D Astigmatism;
- < 1.00D Anisometropia (difference between the two eyes);
- Willing to be randomized;
- Best corrected visual acuity of 20/25 or better in each eye;
- Willing to wear eyeglasses full-time;
- Willing to return for follow-up visits
Exclusion Criteria
- Previous wear of glasses or contacts for farsightedness/hyperopia;
- Eye disease that affects visual function;
- Amblyopia (lazy eye);
- Strabismus (eye turn);
- History of strabismus surgery;
- Chronic use of any of the following medications:
- Antianxiety agents (Librium, Valium)
- Antiarrythmic agents (Cifenline, Cibenzoline)
- Anticholinergics (Motion sickness patch - scopolamine)
- Bladder spasmolytic (Propiverine)
- Chloroquine
- Phenothiazines (Compazine, Mellaril, Thorazine)
- Tricyclic antidepressants (Elavil, Nortriptyline, Tofranil)
Data sourced from ClinicalTrials.gov (NCT00472212). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.